Regulation of acetylcholine release by muscarinic receptors at the mouse neuromuscular junction depends on the activity of acetylcholinesterase.
Muscarinic acetylcholine receptors (mAChRs) play an important role in regulating the release of acetylcholine (ACh) in various tissues. We used subtype-specific antibodies and a fluorescent-labelled muscarinic toxin to demonstrate that mammalian neuromuscular junction expresses mAChR subtypes M1 to M4, and that localization of all subtypes is highly restricted to the innervated part of the muscle. To elucidate the roles of the mAChR subtypes regulating ACh release, we measured the mean quantal content of endplate potentials in isolated mouse phrenic--hemidiaphragm preparations in which release was reduced by a low Ca2+/high Mg2+ medium. Muscarine decreased evoked ACh release in normal junctions but, depending on the concentration, reduced or increased transmitter release in collagen Q-deficient junctions completely lacking acetylcholinesterase (AChE). Both effects were also seen in normal junctions when AChE was inhibited by various doses of fasciculin-2. Block of mAChRs by atropine had no effect on evoked release at normal junctions, but decreased release at junctions lacking AChE. The muscarine-elicited depression of ACh release in normal junctions was completely abolished by pertussis toxin or methoctramine pretreatment, but was not affected by muscarinic toxin MT-3, thus indicating the involvement of the M2 mAChR. The muscarine-induced increase of ACh release in AChE-deficient junctions was not affected by pertussis toxin, but was completely blocked by MT-7, a specific M1 mAChR antagonist. Our results show that the M1 and M2 mAChRs have opposite presynaptic functions in modulating quantal ACh release, and that regulation of release by the two receptor subtypes depends on the functional state of AChE at the neuromuscular junction.
Minic
Jasmina
J
Institut Fédératif de Neurobiologie Alfred Fessard, Laboratoire de Neurobiologie Cellulaire et Moléculaire, C.N.R.S., U.P.R. 9040, 1 avenue de la Terrasse, 91198 Gif-sur-Yvette cedex, France.
Molgó
Jordi
J
Karlsson
Evert
E
Krejci
Eric
E
D000109:Acetylcholine / Q000378:metabolism*; D000110:Acetylcholinesterase / Q000172:deficiency* / Q000235:genetics; D000200:Action Potentials / Q000187:drug effects / Q000502:physiology; D000818:Animals; D002038:Bungarotoxins / Q000494:pharmacology; D018680:Cholinergic Antagonists / Q000494:pharmacology; D002800:Cholinesterase Inhibitors / Q000494:pharmacology; D003094:Collagen / Q000172:deficiency / Q000235:genetics; D004546:Elapid Venoms / Q000494:pharmacology; D019706:Excitatory Postsynaptic Potentials; D008274:Magnesium / Q000494:pharmacology; D051379:Mice; D018345:Mice, Knockout; D018721:Muscarinic Agonists / Q000494:pharmacology; D009124:Muscle Proteins; D016900:Neurofilament Proteins / Q000378:metabolism; D009469:Neuromuscular Junction / Q000187:drug effects / Q000378:metabolism*; D011976:Receptors, Muscarinic / Q000187:drug effects / Q000378:metabolism*; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology*
D002038:Bungarotoxins; D018680:Cholinergic Antagonists; D002800:Cholinesterase Inhibitors; D004546:Elapid Venoms; D018721:Muscarinic Agonists; D009124:Muscle Proteins; D016900:Neurofilament Proteins; D011976:Receptors, Muscarinic; C419876:muscarinic toxin 7; D003094:Collagen; D000110:Acetylcholinesterase; C114027:COLQ protein, human; D008274:Magnesium; D000109:Acetylcholine